Pfizer’s experimental COVID-19 antiviral treatment is able to reduce the risk of hospitalization or death from the CCP ( Chinese Communist Party ) virus by 89 percent when …
Pfizer’s experimental COVID-19 antiviral treatment is able to reduce the risk of hospitalization or death from the CCP ( Chinese Communist Party) virus by 89 percent when taken shortly after initial symptoms, the company announced on Tuesday in its full analysis of data from the trial. The U.S.-based pharmaceutical company’s final testing results on the drug, known as PAXLOVID, remain consistent with an interim analysis it published last month. Albert Bourla, Pfizer’s chief executive, said in a statement the treatment also appears to be effective against the Omicron variant of the CCP virus, a strain that was first noticed in South Africa last month. “Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that… this potential treatment could be a critical tool to help quell the pandemic,” Bourla said. Health experts have spread concern that Omicron appears to be able to evade the protection of antibodies induced by vaccines.
